Incyte Corp (NASDAQ: INCY) has seen a decline in its stock price by -1.51 in relation to its previous close of 74.30. However, the company has experienced a 2.52% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-02-20 that WILMINGTON, Del. & BURLINGAME, Calif.–(BUSINESS WIRE)–Incyte and Genesis Therapeutics announce strategic AI-focused research collaboration.
Is It Worth Investing in Incyte Corp (NASDAQ: INCY) Right Now?
The price-to-earnings ratio for Incyte Corp (NASDAQ: INCY) is above average at 269.84x, Company’s 36-month beta value is 0.76.Analysts have differing opinions on the stock, with 10 analysts rating it as a “buy,” 2 as “overweight,” 15 as “hold,” and 0 as “sell.”
The public float for INCY is 190.70M, and currently, short sellers hold a 4.36% ratio of that floaft. The average trading volume of INCY on February 28, 2025 was 1.68M shares.
INCY’s Market Performance
INCY’s stock has seen a 2.52% increase for the week, with a 0.04% rise in the past month and a 2.04% gain in the past quarter. The volatility ratio for the week is 2.84%, and the volatility levels for the past 30 days are at 3.27% for Incyte Corp The simple moving average for the past 20 days is 1.28% for INCY’s stock, with a 9.23% simple moving average for the past 200 days.
Analysts’ Opinion of INCY
Many brokerage firms have already submitted their reports for INCY stocks, with UBS repeating the rating for INCY by listing it as a “Neutral.” The predicted price for INCY in the upcoming period, according to UBS is $77 based on the research report published on December 17, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see INCY reach a price target of $90, previously predicting the price at $68. The rating they have provided for INCY stocks is “Buy” according to the report published on October 29th, 2024.
Wolfe Research gave a rating of “Outperform” to INCY, setting the target price at $84 in the report published on October 01st of the previous year.
INCY Trading at 2.44% from the 50-Day Moving Average
After a stumble in the market that brought INCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.83% of loss for the given period.
Volatility was left at 3.27%, however, over the last 30 days, the volatility rate increased by 2.84%, as shares sank -0.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.32% upper at present.
During the last 5 trading sessions, INCY rose by +2.52%, which changed the moving average for the period of 200-days by +36.79% in comparison to the 20-day moving average, which settled at $72.25. In addition, Incyte Corp saw 5.95% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INCY starting from SHEILA DENTON, who proposed sale 14,069 shares at the price of $74.07 back on Feb 26 ’25. After this action, SHEILA DENTON now owns shares of Incyte Corp, valued at $1,042,138 using the latest closing price.
Stein Steven H, the EVP & Chief Medical Officer of Incyte Corp, sale 12,352 shares at $72.69 during a trade that took place back on Jan 21 ’25, which means that Stein Steven H is holding 66,967 shares at $897,867 based on the most recent closing price.
Stock Fundamentals for INCY
Current profitability levels for the company are sitting at:
- 0.01 for the present operating margin
- 0.92 for the gross margin
The net margin for Incyte Corp stands at 0.01. The total capital return value is set at 0.02. Equity return is now at value 0.76, with 0.53 for asset returns.
Based on Incyte Corp (INCY), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 7.7. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 27.31.
Currently, EBITDA for the company is 408.16 million with net debt to EBITDA at -6.23. When we switch over and look at the enterprise to sales, we see a ratio of 2.95. The receivables turnover for the company is 4.97for trailing twelve months and the total asset turnover is 0.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.97.
Conclusion
In a nutshell, Incyte Corp (INCY) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
